Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.68 USD | -0.43% | -2.45% | +67.74% |
05-01 | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 | CI |
04-12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
Business Summary
Number of employees: 17
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Delivery Solutions
100.0
%
| 1 | 100.0 % | -3 | 100.0 % | -670.16% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | -3 | 100.0 % | -670.16% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
Anthony DelConte
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Krista Fogarty
AUD | Comptroller/Controller/Auditor | 56 | 18-09-30 |
Corporate Officer/Principal | 55 | 14-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Dana Ono
BRD | Director/Board Member | 71 | 14-01-05 |
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
John W. Higuchi
BRD | Director/Board Member | 56 | 12-12-31 |
Director/Board Member | 66 | 14-01-05 | |
Jill M. Jene
BRD | Director/Board Member | 51 | 22-04-10 |
Chairman | 52 | 22-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,348,276 | 5,192,543 ( 97.09 %) | 336 ( 0.006282 %) | 97.09 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.74% | 25.03M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- LPCN Stock
- Company Lipocine Inc.